πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

6,931 results for β€œThe” Clear

  1. the Shouhui Tongbian Capsule

    The First People's Hospital of Lianyungang

    OIC

    phase 3 small molecule active

    1 trial
  2. ticagrelor

    The First People's Hospital of Lianyungang

    Coronary Artery Disease

    phase 3 small molecule active

    1 trial
  3. tividenofusp alfa

    Denali Therapeutics

    Mucopolysaccharidosis II

    phase 3 small molecule active

    3 trials
  4. trastuzumab

    United Therapeutics Europe Ltd

    Breast Cancer

    phase 3 mab active

    1 trial
  5. treprostinil sodium

    United Therapeutics Europe Ltd

    Liver Transplant

    phase 3 small molecule terminated

    1 trial
  6. ublituximab

    TG THERAPEUTICS, INC.

    relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial
  7. ublituximab, DEXAMETHASONE, PARACETAMOL, GADOBUTROL, ublituximab placebo, DIPHENHYDRAMINE, CETIRIZINE, METHYLPREDNISOLONE

    TG THERAPEUTICS, INC.

    Relapsing multiple sclerosis

    phase 3 small molecule active

    1 trial
  8. venetoclax

    The First People's Hospital of Lianyungang

    Acute Promyelocytic Leukemia

    phase 3 small molecule active

    1 trial
  9. vitamin A supplementation (15,000 ug retinol equivalents or 50,000 IU)

    United Therapeutics Europe Ltd

    Mortality Through Six Months of Age

    phase 3 other completed

    1 trial
  10. xevinapant, Xevinapant Placebo

    Merck Sharp and Dohme

    Resected squamous cell carcinoma of the head and neck

    phase 3 small molecule active

    1 trial
  11. zeleciment basivarsen (DYNE-101)

    Dyne Therapeutics

    Myotonic Dystrophy Type 1 (DM1)

    phase 3 small molecule active

    1 trial
  12. ziltivekimab, Ziltivekimab

    NovoThirteen

    The medical condition we are investigating is type 1 AMI (STEMI and NSTEMI). Ziltivekimab is a human monoclonal antibody directed against the interleukin-6 (IL-6) ligand, and currently available clinical data support that ziltivekimab once-monthly reduces inflammation as measured by highsensitivity C-reactive protein (hs-CRP). With the recent proof-of-concept that hs-CRP reduction through inhibition of an upstream pathway leads to reduction in cardiovascular events, it is reasonable to expect that similar inhibition of IL-6 with ziltivekimab also reduces CV risk.The aim of the current study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major adverse cardiovascular events when initiated as early as possible in adult patients with ST-elevation and non-ST-elevation myocardial infarction

    phase 3 small molecule active

    1 trial
  13. zinc sulphate dietary supplement

    United Therapeutics Europe Ltd

    Nutrition

    phase 3 small molecule completed

    1 trial
  14. zorevunersen

    Stoke Therapeutics

    Dravet Syndrome

    phase 3 small molecule active

    1 trial
  15. "Endostar"

    The First People's Hospital of Lianyungang

    Esophageal

    phase 2 small molecule terminated

    1 trial
  16. (Z)-endoxifen

    ATOSSA THERAPEUTICS, INC.

    Breast Neoplasms

    phase 2 small molecule active

    1 trial
  17. -

    The George Institute

    Cytomegalovirus infection post allogeneic allogeneic HLA-identical familial PHT

    phase 2 small molecule active

    1 trial
  18. -, -, CIMETIDINE , ROXATIDINE , FAMOTIDINE, COMBINATIONS, PARACETAMOL , RANITIDINE , NIZATIDINE , SKB264, FAMOTIDINE , -

    Lacuna Pharma Pty Ltd

    Metastatic or locally advanced unresectable solid tumors progressing after available standard therapies

    phase 2 small molecule active

    1 trial
  19. -, ABIRATERONE, DEGARELIX, RELUGOLIX, APALUTAMIDE, ABIRATERONE, ENZALUTAMIDE, ENZALUTAMIDE, ENZALUTAMIDE, AAA802, AAA502, Locametz 25 micrograms kit for radiopharmaceutical preparation, DEGARELIX ACETATE, DAROLUTAMIDE

    Novartis Pharmaceuticals

    PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and metastatic Castration-resistant Prostate Cancer (mCRPC) with or without prior 177Lu-PSMA radioligand therapy.

    phase 2 small molecule active

    1 trial
  20. -, CYCLOPHOSPHAMIDE, Cesnicabtagene autoleucel, PARACETAMOL, FLUDARABINE, LENALIDOMIDE, RoActemra 20 mg/mL concentrate for solution for infusion

    The George Institute

    Plasma cell leukaemia

    phase 2 small molecule active

    1 trial
  21. -, DNL593 Placebo, Sterile lyophilisate in single-dose glass vials, -, FAMOTIDINE

    Denali Therapeutics

    Frontotemporal Dementia (FTD)

    phase 2 small molecule active

    1 trial
  22. -, Pred Forte 10 mg/ml colirio en suspensiΓ³n

    AbbVie Deutschland GmbH & Co. KG

    platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers.

    phase 2 small molecule active

    1 trial
  23. 0.5% Ivermectin lotion

    United Therapeutics Europe Ltd

    Pediculosis Capitis

    phase 2 small molecule completed

    1 trial
  24. 0.9% sodium chloride

    The First People's Hospital of Lianyungang

    Kidney Disease, Chronic

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources